Vertex Pharmaceuticals Incorporated (VRTX)

Vertex has almost no weak spots thanks to a solid core franchise and several promising programs. DexCom is helping improve the lives of diabetes patients, and the company still has lots of room to gro...

Brookfield Infrastructure should deliver strong organic growth and continue to expand via acquisitions. Microsoft is a leader in nearly all of the top technologies of the future.

Vertex's (VRTX) Kaftrio gets a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for extended use to treat younger age groups of two to five years ol...

Amazon should deliver strong growth over the short term and long term. Mastercard's moat and growth opportunities make it an attractive pick.

Vertex Pharmaceuticals has many avenues for chasing growth both big and small. Its cystic fibrosis medicines continue to remain a rock-solid base of revenue.

Vertex and Regeneron have delivered solid financial results and stock market performance. Both biotechs have exciting pipelines that should produce key new approvals or label expansions.

Vertex Pharmaceuticals is trying to replicate its winning cystic fibrosis formula in other areas. These efforts could yield even better financial results than its potential gene-editing therapy.

September is not known as a good month to buy stocks. In fact, historically it's the worst month.

Pharma companies often have detailed plans for when new revenue will occur. They also sometimes describe periods when sales will be shrinking.

In the grand tapestry of the investment world, one thread that continues to shine is biotech stocks to buy and hold. It's no secret that delving into biotech investments can be incredibly challenging,...